1. Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children

   • Lisa A. Prosser
   • James K. Hammitt
   • Ron Keren

   Leading Article 22 September 2012 Pages: 713 - 726

   

2. The Increasingly Complex Fourth Hurdle for Pharmaceuticals

   • Joshua Cohen
   • Elly Stolk
   • Maartje Niezen

   Current Opinion 22 September 2012 Pages: 727 - 734

3. Modelling Disease Progression in Alzheimer’s Disease

   • Colin Green

   Review Article 22 September 2012 Pages: 735 - 750

   

4. Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus

   • Andrew F. Shorr

   Review Article 22 September 2012 Pages: 751 - 768

   

5. Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention

   • Bart M. S. Heeg
   • Ron J. G. Peters
   • Ben A. van Hout

   Original Research Article 22 September 2012 Pages: 769 - 782

   

6. Preferences of Community Pharmacists for Extended Roles in Primary Care

   • Anthony Scott
   • Christine Bond
   • Aileen Grant

   Original Research Article 22 September 2012 Pages: 783 - 792

   

7. Reliability of Medicaid Claims Versus Medical Record Data

   • Julie Jacobson Vanna
   • John Feaganes
   • Steven Wegner

   Original Research Article 22 September 2012 Pages: 793 - 800

   

8. A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

   • Philip Home
   • Adrian Bagust
   • Samara Mendes da Costa

   Correspondence 22 September 2012 Pages: 801 - 802

9. The Authors’ Reply

   • Dominic P. Tilden
   • Segundo Mariz
   • Alexander Diamantopoulos

   Correspondence 22 September 2012 Pages: 802 - 805